Samsung Biologics (207940) Insider Transactions
The most recent insider transactions at Samsung Biologics include purchases filed with FSC/FSS under MAR Article 19. In November 2026, Jon Rim (CEO) bought 12 shares worth ₩14M.
Last updated: 2026-11-20 · Data sourced from MAR Article 19 regulatory disclosures
🔔 Get alerts for Samsung Biologics
Be notified when insiders buy or sell Samsung Biologics. Free for up to 3 stocks.
Recent Insider Transactions at Samsung Biologics
| Date | Insider | Role | Type | Shares | Price | Value | Signals |
|---|---|---|---|---|---|---|---|
| 2026-11-17 | Jon Rim | CEO | BUY | 12 | ₩1M | ₩14M | — |
| 2026-11-17 | No Gyun | President | BUY | 2 | ₩1M | ₩2M | — |
| 2026-11-17 | Yu Seungho | President | BUY | 6 | ₩1M | ₩7M | — |
| 2026-11-03 | Gim Huijeong | Executive Director | SELL | 10 | ₩272,600 | ₩3M | — |
| 2026-11-03 | Je Imseuchoe | President | SELL | 25 | ₩295,000 | ₩7M | — |
Showing last 5 transactions · View all in app →
Live filings with conviction scores, signal badges, and post-trade return tracking.
Insiders Tracked at Samsung Biologics
About This Data
InsidersAlpha tracks insider transactions at Samsung Biologics filed with FSC/FSS under MAR Article 19. Data is sourced directly from official regulatory filings and updated daily. All 9 transactions on record include 3 insider purchases and 6 sales.
The largest single transaction recorded was worth ₩74M by Jo Seonghwan on 2026-07-31.
Frequently Asked Questions
Who are the insiders trading Samsung Biologics stock?
Known insiders at Samsung Biologics include Jon Rim (CEO), No Gyun (President), Yu Seungho (President), Gim Huijeong (Executive Director), Je Imseuchoe (President). InsidersAlpha tracks 5 named insiders at Samsung Biologics.
When was the last insider buy at Samsung Biologics?
The most recent insider purchase at Samsung Biologics was by Jon Rim (CEO) on 2026-11-17, buying 12 shares at ₩1M for a total of ₩14M. InsidersAlpha updates daily from official FSC/FSS disclosures.
How many insider transactions has Samsung Biologics had?
Samsung Biologics has had 9 insider transactions tracked on InsidersAlpha, including 3 purchases and 6 sales. The overall buy/sell ratio is 33% buys.
What is the insider buying trend at Samsung Biologics?
Over the past 6 months, Samsung Biologics insiders have made 3 purchases totaling ₩23M. The insider activity trend is mixed — showing both buying and selling (3 buys vs 6 sells). Past performance does not guarantee future results — always conduct your own research.